CRBU — Caribou Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1619856 ·
Last close
$1.24
Market Cap
$132.94M
52W High
$3.54
52W Low
$1.22
ADV30
1,141,343
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,499,000 | — | -25,339,000 | -24,282,000 | 142,774,000 | 26,194,000 | 44,672,000 |
| Mar 2026 | 2,397,000 | — | -26,280,000 | -25,085,000 | 148,998,000 | 12,057,000 | 46,980,000 |
| Dec 2025 | 3,941,000 | — | -28,453,000 | -26,488,000 | 175,367,000 | 12,360,000 | 53,192,000 |
| Sep 2025 | 2,198,000 | — | -29,400,000 | -27,548,000 | 194,984,000 | 11,144,000 | 53,139,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-101,251,000
Investing CF
$76,842,000
Financing CF
$7,049,000
CapEx
$-1,647,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.42
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-621,600,000
Inventory
—
Receivables
$2,363,000
ST Investments
$105,569,000
EBIT TTM
$-119,561,000
Pretax Income TTM
$-133,769,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$10,035,000
EBITDA
$-104,609,000
Free Cash Flow
$-59,605,500
Enterprise Value
$50,494,540
Total Cash
$112,314,000
Total Debt
$26,655,000
Shares Out
107,207,513
Trailing EPS
$-1.08
Book Value
$0.93
ROE
-78.3%
ROA
-36.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 11,159,000 | -136,194,000 | -148,125,000 | 175,367,000 | 53,192,000 | 122,175,000 | -110,992,000 |
| Dec 2024 | 9,994,000 | -166,616,000 | -149,105,000 | 313,313,000 | 60,362,000 | 252,951,000 | -138,200,000 |
| Dec 2023 | 34,477,000 | -116,059,000 | -102,070,000 | 432,209,000 | 63,808,000 | 368,401,000 | -93,291,000 |
| Dec 2022 | 13,851,000 | -106,399,000 | -99,421,000 | 373,765,000 | 72,894,000 | 300,871,000 | -90,966,000 |
TTM Snapshot
Revenues TTM
$31,342,000
NetIncome TTM
$-111,324,000
OpCashFlow TTM
$0
Assets (Latest)
$175,367,000
Forward EPS
$-1.26
Max Pain — expiry 2026-10-16
max pain strike: $2.00 · spot: $1.24 · call oi: 1,683 · put oi: 660Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ENGN | enGene Therapeutics Inc. | $131.35M | $1.96 | — |
| TNYA | Tenaya Therapeutics, Inc. | $136.78M | $0.61 | — |
| NMRA | Neumora Therapeutics, Inc. | $127.39M | $0.68 | — |
| ARMP | Armata Pharmaceuticals, Inc. | $139.06M | $3.74 | — |
| LENZ | LENZ Therapeutics, Inc. | $123.01M | $3.91 | — |
News headlines (Yahoo Finance, 1h cache)
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 22:05 · Yahoo
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-13 20:05 · Yahoo
BMS and Gilead rule in the CAR-T space. Off-the-shelf developers aren’t trying to change that.
2026-07-29 13:49 · Yahoo
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year?
2026-07-09 13:40 · Yahoo
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
2026-06-29 12:00 · Yahoo
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
2026-06-11 12:01 · Yahoo
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
2026-06-11 12:00 · Yahoo
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
2026-06-09 10:04 · Yahoo
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-27 20:05 · Yahoo
Industry Analysts Just Made A Massive Upgrade To Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Revenue Forecasts
2026-05-13 12:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.